Signaling through ShcA Is Required for Transforming Growth Factor β- and Neu/ErbB-2-Induced Breast Cancer Cell Motility and Invasion
暂无分享,去创建一个
W. Muller | P. Siegel | C. Russo | J. Chmielecki | J. J. Northey | M. Annis | E. Ngan
[1] R. Cardiff,et al. Distinct ErbB-2 coupled signaling pathways promote mammary tumors with unique pathologic and transcriptional profiles. , 2007, Cancer research.
[2] C. Hudis. Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.
[3] C. Sotiriou,et al. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? , 2007, Nature Reviews Cancer.
[4] T. Pawson,et al. Screening for PTB Domain Binding Partners and Ligand Specificity Using Proteome-Derived NPXY Peptide Arrays , 2007, Molecular and Cellular Biology.
[5] Robert D. Cardiff,et al. Insights from transgenic mouse models of ERBB2-induced breast cancer , 2007, Nature Reviews Cancer.
[6] R. Caprioli,et al. Multivariable Difference Gel Electrophoresis and Mass Spectrometry , 2007, Molecular & Cellular Proteomics.
[7] T. Pawson,et al. Screening for PTB Domain Binding Partners and LigandSpecificity Using Proteome-Derived NPXY Peptide Arrays , 2006, Molecular and Cellular Biology.
[8] Frederick Y. Wu,et al. HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by transforming growth factor beta. , 2006, Cancer research.
[9] David R Critchley,et al. The structure and regulation of vinculin. , 2006, Trends in cell biology.
[10] Brian Bierie,et al. Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer , 2006, Nature Reviews Cancer.
[11] R. Liddington,et al. Role of vinculin in regulating focal adhesion turnover. , 2006, European journal of cell biology.
[12] M. Barcellos-Hoff,et al. Activated type I TGFβ receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression , 2006, Oncogene.
[13] Gavin MacBeath,et al. A quantitative protein interaction network for the ErbB receptors using protein microarrays , 2006, Nature.
[14] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[15] H. Beug,et al. Molecular requirements for epithelial-mesenchymal transition during tumor progression. , 2005, Current opinion in cell biology.
[16] Andrés J. García,et al. Cell adhesion strengthening: contributions of adhesive area, integrin binding, and focal adhesion assembly. , 2005, Molecular biology of the cell.
[17] C. Heldin,et al. Non-Smad TGF-β signals , 2005, Journal of Cell Science.
[18] M. Mann,et al. Phosphotyrosine interactome of the ErbB-receptor kinase family , 2005, Molecular systems biology.
[19] Morag Park,et al. CrkI and CrkII Function as Key Signaling Integrators for Migration and Invasion of Cancer Cells , 2005, Molecular Cancer Research.
[20] C. Arteaga,et al. Overexpression of HER2 (erbB2) in Human Breast Epithelial Cells Unmasks Transforming Growth Factor β-induced Cell Motility* , 2004, Journal of Biological Chemistry.
[21] L. Addadi,et al. Hierarchical assembly of cell-matrix adhesion complexes. , 2004, Biochemical Society transactions.
[22] N. Hynes,et al. Memo mediates ErbB2-driven cell motility , 2004, Nature Cell Biology.
[23] N. Carragher,et al. Focal adhesion and actin dynamics: a place where kinases and proteases meet to promote invasion. , 2004, Trends in cell biology.
[24] Yosef Yarden,et al. Signal transduction and oncogenesis by ErbB/HER receptors. , 2004, International journal of radiation oncology, biology, physics.
[25] Joshua LaBaer,et al. Cooperation of the ErbB2 receptor and transforming growth factor beta in induction of migration and invasion in mammary epithelial cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[26] Martin Bastmeyer,et al. Cell behaviour on micropatterned substrata: limits of extracellular matrix geometry for spreading and adhesion , 2004, Journal of Cell Science.
[27] Dana M. Brantley-Sieders,et al. Increased Malignancy of Neu-Induced Mammary Tumors Overexpressing Active Transforming Growth Factor β1 , 2003, Molecular and Cellular Biology.
[28] J. Massagué,et al. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer , 2003, Nature Reviews Cancer.
[29] Philip M. Long,et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[30] F. Maurer,et al. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[31] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[32] R. Cardiff,et al. Transforming growth factor β signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[33] J. Massagué,et al. Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus , 2003, Cell.
[34] C. Arteaga,et al. p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. , 2002, Journal of cell science.
[35] L. Wakefield,et al. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. , 2002, The Journal of clinical investigation.
[36] W. Muller,et al. Multiple ErbB-2/Neu Phosphorylation Sites Mediate Transformation through Distinct Effector Proteins* , 2001, The Journal of Biological Chemistry.
[37] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[38] K. Beningo,et al. Nascent Focal Adhesions Are Responsible for the Generation of Strong Propulsive Forces in Migrating Fibroblasts , 2001, The Journal of cell biology.
[39] L. Addadi,et al. Force and focal adhesion assembly: a close relationship studied using elastic micropatterned substrates , 2001, Nature Cell Biology.
[40] M. Moran,et al. Grb2 and Shc Adapter Proteins Play Distinct Roles in Neu (ErbB-2)-Induced Mammary Tumorigenesis: Implications for Human Breast Cancer , 2001, Molecular and Cellular Biology.
[41] S. Sadekova,et al. Distinct tyrosine autophosphorylation sites mediate induction of epithelial mesenchymal like transition by an activated ErbB-2/Neu receptor , 2001, Oncogene.
[42] H. Moses,et al. Phosphatidylinositol 3-Kinase Function Is Required for Transforming Growth Factor β-mediated Epithelial to Mesenchymal Transition and Cell Migration* , 2000, The Journal of Biological Chemistry.
[43] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[44] D. Cheresh,et al. Bifurcation of Cell Migratory and Proliferative Signaling by the Adaptor Protein Shc , 1999, The Journal of cell biology.
[45] T. Pawson,et al. Accelerated Mammary Tumor Development in Mutant Polyomavirus Middle T Transgenic Mice Expressing Elevated Levels of Either the Shc or Grb2 Adapter Protein , 1999, Molecular and Cellular Biology.
[46] R. Cardiff,et al. Elevated expression of activated forms of Neu/ErbB‐2 and ErbB‐3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer , 1999, The EMBO journal.
[47] E. Adamson,et al. Rescue of the mutant phenotype by reexpression of full-length vinculin in null F9 cells; effects on cell locomotion by domain deleted vinculin. , 1998, Journal of cell science.
[48] John N. Hutchinson,et al. Requirement for Both Shc and Phosphatidylinositol 3′ Kinase Signaling Pathways in Polyomavirus Middle T-Mediated Mammary Tumorigenesis , 1998, Molecular and Cellular Biology.
[49] S. Bull,et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] E. Adamson,et al. Vinculin knockout results in heart and brain defects during embryonic development. , 1998, Development.
[51] M. Moran,et al. Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation , 1997, Molecular and cellular biology.
[52] M. Shibuya,et al. Tyrosine phosphorylation sites at amino acids 239 and 240 of Shc are involved in epidermal growth factor-induced mitogenic signaling that is distinct from Ras/mitogen-activated protein kinase activation , 1997, Molecular and cellular biology.
[53] Tony Pawson,et al. The Shc adaptor protein is highly phosphorylated at conserved, twin tyrosine residues (Y239/240) that mediate protein–protein interactions , 1996, Current Biology.
[54] R. Ezzell,et al. Targeted disruption of vinculin genes in F9 and embryonic stem cells changes cell morphology, adhesion, and locomotion. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[55] R. Derynck,et al. TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors , 1994, The Journal of cell biology.
[56] W. Muller,et al. Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. , 1994, Molecular and Cellular Biology.
[57] T Pawson,et al. Formation of Shc-Grb2 complexes is necessary to induce neoplastic transformation by overexpression of Shc proteins. , 1994, Oncogene.
[58] R. Cardiff,et al. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[59] R. Cardiff,et al. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease , 1992, Molecular and cellular biology.
[60] S. Aaronson,et al. The carboxy-terminal domains of erbB-2 and epidermal growth factor receptor exert different regulatory effects on intrinsic receptor tyrosine kinase function and transforming activity. , 1990, Molecular and cellular biology.
[61] P. Jolicoeur,et al. Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene , 1989, Cell.
[62] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[63] Cori Bargmann,et al. Oncogenic activation of the neu‐encoded receptor protein by point mutation and deletion. , 1988, The EMBO journal.
[64] P. Leder,et al. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.
[65] Cori Bargmann,et al. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185 , 1986, Cell.
[66] C. Hoge,et al. THE NEW ENGLAND JOURNAL OF MEDICINE , 1977, The Lancet.
[67] H. Smith,et al. Epithelial cell cultures from normal glandular tissue of mice. , 1974, Journal of the National Cancer Institute.
[68] R. Caprioli,et al. Multivariable Difference Gel Electrophoresis and Mass Spectrometry A CASE STUDY ON TRANSFORMING GROWTH FACTOR- (cid:1) AND ERBB2 SIGNALING* □ S , 2006 .
[69] Y. Shyr,et al. Transforming growth factor beta-regulated gene expression in a mouse mammary gland epithelial cell line , 2003, Breast Cancer Research.
[70] J. Wrana,et al. TGF-beta and the Smad signal transduction pathway. , 2002, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[71] H. Moses,et al. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. , 2001, Molecular biology of the cell.
[72] P. Ravdin. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer , 1999 .
[73] B. Geiger,et al. Overexpression of vinculin suppresses cell motility in BALB/c 3T3 cells. , 1992, Cell motility and the cytoskeleton.
[74] A. Ullrich,et al. Identification of autophosphorylation sites of HER2/neu. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[75] M. Sporn,et al. Transforming growth factor beta. , 1988, Advances in cancer research.
[76] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[77] Frederick Y. Wu,et al. Transforming Growth Factor (cid:2) (TGF- (cid:2) )-Smad Target Gene Protein Tyrosine Phosphatase Receptor Type Kappa Is Required for TGF- (cid:2) Function† , 2022 .